Laurus Labs Stock Screener | Share Price & Fundamental Analysis
LAURUSLABS
Pharmaceuticals
Share Price NSE
₹1082.45
▲
25.00 (2.36%)
Share Price BSE
₹1082.85
▲
26.45 (2.50%)
Track Laurus Labs share price live with TickJournal's free stock screener.
Analyze Laurus Labs share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Laurus Labs Market Cap
₹56,301.64 Cr.
LAURUSLABS P/E Ratio (TTM)
66.75
Laurus Labs P/B Ratio
11.68
EPS (TTM)
₹6.65
Dividend Yield
0.12%
Debt to Equity
0.62
LAURUSLABS 52 Week High
₹1128.50
Laurus Labs 52 Week Low
₹586.75
Operating Margin
27.00%
Profit Margin
14.13%
LAURUSLABS Revenue (TTM)
₹1,784.00
EBITDA
₹486.00
Net Income
₹252.00
Total Assets
₹9,336.00
Total Equity
₹4,603.00
Laurus Labs Share Price History - Stock Screener Chart
Screen LAURUSLABS historical share price movements with interactive charts. Analyze price trends and patterns.
Laurus Labs Company Profile - Fundamental Screener
Screen Laurus Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for LAURUSLABS shares.
Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company based in India. It operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis, and Ingredients. The company specializes in active pharmaceutical ingredients (APIs) for anti-retrovirals, Hepatitis C, and Oncology, among other therapeutic areas. Laurus Labs...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Ravindranath Kancherla
ISIN
INE947Q01028
Website
https://www.lauruslabs.com
Laurus Labs Balance Sheet Screener
Screen LAURUSLABS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 9,336 | 8,387 | 7,660 | 6,968 | 5,751 | 3,750 | 3,331 | 3,017 | 2,653 | 2,224 |
| Current Assets | 4,332 | 3,835 | 3,462 | 3,345 | 3,075 | 1,812 | 1,463 | 1,248 | 1,140 | 1,003 |
| Fixed Assets | 4,123 | 3,890 | 3,409 | 2,653 | 2,171 | 1,726 | 1,629 | 1,481 | 1,230 | 1,021 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1,193 | 1,159 | 1,180 | 928 | 693 | 288 | 349 | 227 | 202 | 483 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 4,603 | 4,116 | 4,049 | 3,359 | 2,601 | 1,770 | 1,558 | 1,483 | 1,330 | 857 |
| Share Capital | 108 | 108 | 108 | 108 | 107 | 107 | 106 | 106 | 106 | 82 |
| Reserves & Surplus | 4,365 | 4,003 | 3,930 | 3,244 | 2,490 | 1,658 | 1,447 | 1,371 | 1,225 | 774 |
Laurus Labs Income Statement Screener - Profit & Revenue Analysis
Screen Laurus Labs income statement and profit fundamentals.
Analyze LAURUSLABS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Laurus Labs share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,784 | 1,680 | 1,580 | 1,779 | 1,425 | 1,228 | 1,197 | 1,458 | 1,197 | 1,226 | 1,185 | 1,383 | 1,546 | 1,577 | 1,541 |
| Expenses | 1,298 | 1,250 | 1,187 | 1,300 | 1,130 | 1,045 | 1,024 | 1,198 | 1,014 | 1,037 | 1,015 | 1,095 | 1,141 | 1,127 | 1,085 |
| EBITDA | 486 | 430 | 393 | 479 | 295 | 183 | 174 | 260 | 184 | 190 | 170 | 287 | 405 | 450 | 456 |
| Operating Profit % | 27.00% | 24.00% | 24.00% | 24.00% | 20.00% | 15.00% | 14.00% | 17.00% | 15.00% | 15.00% | 14.00% | 21.00% | 26.00% | 28.00% | 30.00% |
| Depreciation | 121 | 121 | 117 | 110 | 106 | 108 | 106 | 102 | 98 | 93 | 91 | 87 | 84 | 82 | 71 |
| Interest | 39 | 40 | 52 | 56 | 58 | 53 | 49 | 51 | 51 | 42 | 39 | 53 | 43 | 40 | 29 |
| Profit Before Tax | 327 | 270 | 224 | 312 | 131 | 23 | 19 | 107 | 35 | 54 | 41 | 147 | 278 | 328 | 356 |
| Tax | 75 | 75 | 63 | 80 | 38 | 3 | 6 | 32 | 11 | 17 | 14 | 42 | 75 | 95 | 104 |
| Net Profit | 252 | 195 | 162 | 233 | 93 | 20 | 13 | 75 | 23 | 37 | 27 | 105 | 203 | 233 | 252 |
| EPS | 4.67 | 3.61 | 3.02 | 4.34 | 1.71 | 0.37 | 0.23 | 1.40 | 0.43 | 0.69 | 0.46 | 1.90 | 3.78 | 4.33 | 4.68 |
Laurus Labs Cash Flow Screener - Liquidity Fundamentals
Screen LAURUSLABS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 602 | 666 | 994 | 911 | 733 | 347 | 298 | 343 | 332 | 182 |
| Investing Activities | -680 | -822 | -997 | -915 | -941 | -221 | -253 | -384 | -289 | -312 |
| Financing Activities | 39 | 250 | -27 | 30 | 255 | -128 | -45 | 42 | -54 | 103 |
| Net Cash Flow | -39 | 93 | -30 | 27 | 47 | -1 | 0 | 1 | -10 | -27 |
Laurus Labs Shareholding Pattern Screener
See Laurus Labs shareholding pattern with promoter, FII, and DII holdings.
Check Laurus Labs promoter holding and ownership changes for LAURUSLABS on TickJournal.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 27.49% | 27.59% | 27.59% | 27.62% | 27.62% | 27.18% | 27.18% | 27.19% |
| FII Holding | 26.52% | 26.16% | 25.70% | 25.52% | 25.56% | 26.08% | 25.67% | 25.97% |
| DII Holding | 12.43% | 11.73% | 11.94% | 11.77% | 12.74% | 13.05% | 13.56% | 11.77% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 22.64% | 23.33% | 23.12% | 23.65% | 22.72% | 22.67% | 22.68% | 23.95% |
| Other Holding | 10.92% | 11.18% | 11.65% | 11.44% | 11.36% | 11.03% | 10.91% | 11.12% |
| Shareholder Count | 280,756 | 283,678 | 280,223 | 292,905 | 292,214 | 309,063 | 324,059 | 356,830 |
Laurus Labs Share Dividend Screener - Share Yield Analysis
Check Laurus Labs dividend history with payout and yield data.
View Laurus Labs dividend details including ex-dates and amounts for LAURUSLABS stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.20 | 0.12% |
| 2024-March | ₹0.80 | 0.13% |
| 2023-March | ₹2.00 | 0.51% |
| 2022-March | ₹2.00 | 0.67% |
| 2021-March | ₹2.00 | 0.34% |
| 2020-March | ₹2.50 | 0.69% |
| 2019-March | ₹1.50 | 2.31% |
| 2018-March | ₹1.50 | 1.88% |
| 2017-March | ₹1.50 | 1.49% |
Laurus Labs Stock Index Membership
See which indices include Laurus Labs stock.
Check LAURUSLABS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX BSEMOI
BSE INDEX MIDCAP
BSE INDEX MSL400
BSE INDEX SML250
NIFTY 500
NIFTY HEALTHCARE
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MULTI MFG
NIFTY PHARMA
NIFTY SMLCAP 100
NIFTY SMLCAP 250
NIFTY SMLCAP 50
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
Laurus Labs Market Events Screener - Corporate Actions
Get Laurus Labs corporate actions including splits, bonuses, and buybacks.
Check Laurus Labs stock events that may affect LAURUSLABS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-01-23 | 2026-01-23 | Quarterly Result Announcement | NA | -8.72% |
| 2025-10-31 | 2025-10-31 | Dividend | ₹ 0.80 /share | 5.03% |
| 2025-10-23 | 2025-10-23 | Quarterly Result Announcement | NA | 7.65% |
| 2025-07-25 | 2025-07-25 | Quarterly Result Announcement | NA | 7.48% |
| 2025-06-26 | 2025-06-26 | Annual General Meeting | NA | 10.52% |
| 2025-05-09 | 2025-05-09 | Dividend | ₹ 0.80 /share | -9.91% |
| 2025-04-24 | 2025-04-24 | Quarterly Result Announcement | NA | 15.28% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | -4.35% |
| 2024-11-06 | 2024-11-06 | Dividend | ₹ 0.40 /share | 8.88% |
| 2024-10-24 | 2024-10-24 | Quarterly Result Announcement | NA | -6.44% |
| 2024-07-11 | 2024-07-11 | Annual General Meeting | NA | 8.77% |
| 2024-05-08 | 2024-05-08 | Dividend | ₹ 0.40 /share | -1.14% |
| 2023-11-02 | 2023-11-02 | Dividend | ₹ 0.40 /share | -9.46% |
| 2023-05-10 | 2023-05-10 | Dividend | ₹ 1.20 /share | 11.41% |
| 2022-11-03 | 2022-11-04 | Dividend | ₹ 0.80 /share | -9.21% |
Laurus Labs Competitors Screener - Peer Comparison
Screen LAURUSLABS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 406,351 | 37.86 | 54,729 | 9.71% | 10,980 | 37.98 |
| Divis Laboratories | 155,472 | 63.26 | 9,712 | 18.67% | 2,191 | 33.24 |
| Torrent Pharmaceuticals | 134,945 | 61.20 | 11,539 | 6.99% | 1,911 | 32.75 |
| Lupin | 103,954 | 22.26 | 22,910 | 13.74% | 3,306 | 47.35 |
| Dr Reddys Laboratories | 101,601 | 18.27 | 33,741 | 16.73% | 5,725 | 39.36 |
| Cipla | 96,320 | 21.31 | 28,410 | 7.12% | 5,291 | 26.86 |
| Zydus Life Science | 86,964 | 17.29 | 23,511 | 18.55% | 4,615 | 41.42 |
| Mankind Pharma | 82,499 | 45.81 | 12,744 | 20.90% | 2,007 | 41.40 |
| Aurobindo Pharma | 77,462 | 22.37 | 32,346 | 9.43% | 3,484 | 64.38 |
| Alkem Laboratories | 62,867 | 25.87 | 13,458 | 3.70% | 2,216 | 42.54 |
Laurus Labs Company Announcements - News Screener
Screen LAURUSLABS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-03 | Closure of Trading Window | - |
| 2026-03-12 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | - |
| 2026-03-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-03-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-24 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-02-23 | Laurus Labs Recognized For Sustainability Leadership By S&P Global | - |
| 2026-02-20 | Intimation Of ESG Score Given By SES ESG Research Private Limited | - |
| 2026-02-20 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-02-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-01-28 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-01-24 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-01-23 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-01-23 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-01-23 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-01-23 | Board Meeting Outcome for Outcome Of The Board Meeting | - |
| 2026-01-23 | Results - Financial Results For Quarter Ended December 31 2025 | - |
| 2026-01-23 | Intimation Of Grant Of Stock Options To The Eligible Employees | - |
| 2026-01-09 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-01-09 | Board Meeting Intimation for Inter-Alia To Consider The Un-Audited Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-01-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |